Actuality: The increase in men's life expectancy is accompanied by an increase in age-related clinical signs and symptoms, such as muscle weakness, osteoporosis, the development of benign prostatic hyperplasia, changes in body composition, fatigue, decreased sexual interest and activity, as well as an increase in the prevalence of erectile dysfunction, all of which limit the quality of life. This condition is called age-related androgen deficiency. This article will provide a brief overview of the results of the study of the effects of the use of the peptide IPH LGA, which can contribute to the normalization of the hormonal male background and improve the quality of life. Purpose: to study the possibilities of the IPH LGA peptide complex. Materials and methods: the study evaluated the molecular and cellular effect, the effect on biological age and markers of aging, the clinical efficacy of the IPH LGA peptide as a protector of hormonal male background. We used German peptides IPH LGA, which have all the approvals and permits for the world markets, such as: WADA certificate (anti-doping), MAFFA certificate (safety), ORGANIC certificate, HALAL certificate, patent protection: patent in the United States - Patent Application Publicatin (United States, No.:US2021/052534A1, date: Feb.25,2021), patent in the European Union No. 016704471, patent in the Russian Federation No. 645608, patent in the People's Republic of China No. 30507522. Results: The use of the IPH LGA peptide has a pronounced oncoprotective character, in particular, in malignant neoplasms of the genitourinary system. The restoration of growth hormone to the maximum possible reference values, up to 4.9 ng/ml, and testosterone levels up to 6.9±0.8 ng/ml, which is 87.4% higher than before and in the control group, against the background of the use of IPH LGA peptide, allows the use of IPH LGA peptide as a preventive and therapeutic drug to normalize hormonal male background with age-related androgen deficiency. The use of the IPH LGA peptide has a protective effect on the testicular cells and increases the fertilizing ability by increasing the activity and number of spermatozoa. Conclusions: Normalization of the hormonal background after the use of the IPH LGA peptide led to an improvement in mood, stability of the emotional background, increased physical health and performance in men by 56.7%, 67.4%, 59.2% and 45.7%, respectively, which was shown when studying the quality of life using the SF-36 questionnaire. The IPH LGA peptide acts as a means leading to the normalization of the hormonal background with age-related changes in men, which improves the quality of life.